LLY Stock Forecast: Mounjaro Momentum

Milana PapadopoulouThis LLY Stock Forecast article was written by Milana Papadopoulou – Financial Analyst at I Know First.

Highlights

  • Eli Lilly posts over 40% revenue growth in 2025, led by GLP-1 therapies Mounjaro and Zepbound
  • Cardiometabolic drugs drive nearly three-quarters of total revenue
  • Novo Nordisk remains the main competitor in diabetes and obesity drugs

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here